Molecular medicine: Antisense-oligonucleotide therapy

New England Journal of Medicine

Volumn 334, Issue 5, 1996, Pages 316-318

  Askari, Frederick K ^a   Mcdonnell, W Michael ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE;

ARTICLE; CARDIOVASCULAR DISEASE; GENE TECHNOLOGY; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; TREATMENT INDICATION;

CARDIOVASCULAR DISEASES; HIV; HIV INFECTIONS; HUMANS; LEUKEMIA; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN BIOSYNTHESIS;

EID: 0030051756     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/nejm199602013340508     Document Type: Article

References (6)

1. Clark RE. Poor cellular uptake of antisense oligodeoxynucleotides: an obstacle to their use in chronic myeloid leukaemia. Leuk Lymphoma 1995;19:189-95.
2. Lu XM, Fischman AJ, Jyawook SL, Hendricks K, Tompkins RG, Yarmush ML. Antisense DNA delivery in vivo: liver targeting by receptor-mediated uptake. J Nucl Med 1994;35:269-75.
3. Palestine AG, Cantrill HL, Luckie AP, Ai E. Intravitreal treatment of CMV retinitis with an antisense oligonucleotide, ISIS 2922. Presented at the 10th International Conference on AIDS, Yokohama, Japan. August 7-12, 1994. abstract.
4. Ratajczak MZ, Kant JA, Luger SM, et al. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A 1992;89:11823-7.
5. Tomita N, Morishita R, Higaki J, et al. Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen. Hypertension 1995;26:131-6.
6. Wagner RW. Gene inhibition using antisense oligodeoxynucleotides Nature 1994;372:333-5.